Aegis Sciences Corporation on LinkedIn: Aegis Clinical Team Members Discuss the Dangers of Tianeptine Misuse with… (2024)

Some healthcare laboratories are starting to expand Novel Psychoactive Substance or NPS testing, even adding some of the fentanyl analogs to their offering, but Aegis has purposefully explored addition of relevant nitazene compounds within our designer opioid menu to ensure we are offering relevant testing.Join us on Tuesday, June 25th, for our monthly clinical webinar presented by Dr. Holt as we discuss new data on nitazenes and ongoing evaluation of this emerging threat.Register Today: https://lnkd.in/ejtCHFuc#AegisLabs #Nitazenes #DesignerOpioids #NPS #OnePillCanKill #PublicSafety #Webinar #LivePresentation #Clinical #Education

27

2 Comments

MDMA, or methylenedioxymethamphetamine, also sometimes referred to as midomafetamine is a synthetic psychoactive drug commonly known as Ecstasy. On 6/4/2024, an advisory panel for the Food and Drug Administration (FDA) rejected its use for treatment on post-traumatic stress disorder (PTSD). A final decision from the FDA is expected in August 2024. MDMA is currently a Schedule I substance which classifies it as having no accepted medical use and high potential for abuse. Regulatory bodies continue to navigate the growing research of psychedelics substances for various mental health diagnoses. Learn more about MDMA from the advisory panel of FDA here: https://lnkd.in/eDBUs48GAegis tests for MDMA and other psychedelic substances in both urine and oral fluid. Learn more today: https://lnkd.in/emXVQJ93#MDMA #AegisLabs #Ecstasy #Psychedelics #MentalHealth #PTSD #Synthetic #NPS

10

Last week, (CFSRE) published an alert regarding 2F-2oxo-PCE, a substance that has similar characteristics to ketamine. This is a drug that is not currently regulated in the United States, produces dissociative effects when used, and has been found in several states across the country.The drug was first identified in Australia, but has since been detected in both drug materials and toxicology samples. Use of this drug has been associated with both intoxication and fatalities, and it has been found alongside other potent, high-risk substances. The CSFRE report states that “…drug materials containing 2F-2oxo-PCE also contained opioids, primarily fentanyl. Xylazine, NPS benzodiazepines, and nitazene analogues were common co-occurrences alongside 2F-2oxo-PCE.”Aegis implemented testing for this drug in September 2023, and in cases where use is suspected, it can be tested in both urine and oral fluid specimens. For more information on our NPS testing, please contact us.#AegisLabs #2F-2oxo-PCE #SubstanceAbuse #Opioids #Fentanyl #Xylazine #Nitazenes #NPS

14

Signs and symptoms of gabapentin misuse or abuse can include the development of tolerance, self-dose escalation, and drug-seeking behavior. Because trends in gabapentin misuse and diversion are especially seen in those with a history of opioid abuse, understanding risk factors of the patient before prescribing can reduce the rate of gabapentin abuse. Gabapentin taken at higher doses can produce varying desired effects, including improved sociability, increased energy, marijuana-like relaxation, or dissociation. Aegis includes gabapentin in their definitive drug testing menu: https://lnkd.in/epgD3KnE#AegisLabs #Alcohol #Amphetamines #Antidepressants #Benzodiazepines #Buprenorphine #Gabapentin #Opioids #Clinical #Educational #Webinar

7

Special attention must be given when prescribing gabapentin for patients who are also taking any drug that results in central nervous system depression. The most common classes include opiates, buprenorphine, benzodiazepines, and antihistamines. When these classes are used concomitantly with gabapentin, there is risk for respiratory depression, potentially resulting in death. In 2022, the FDA administered a warning that patients using gabapentin who have respiratory risk factors may have serious breathing difficulties when used with opioids or other CNS depressants. Learn more from Aegis’ webinar that was just recorded yesterday at: https://lnkd.in/epgD3KnE#AegisLabs #Alcohol #Amphetamines #Antidepressants #Benzodiazepines #Buprenorphine #Gabapentin #Opioids #Clinical #Educational #Webinar #LivePresentation

2

The webinar is TODAY! Please join us today at 11am CT or 1pm CT, when we will be discussing the highlights and challenges of gabapentin, including its usefulness in several disease states, its misuse and abuse potential, and Aegis data demonstrating overall gabapentin positivity and top drug classes co-positive with gabapentin.Register here: https://lnkd.in/epgD3KnE#AegisLabs #Alcohol #Amphetamines #Antidepressants #Benzodiazepines #Buprenorphine #Gabapentin #Opioids #Clinical #Educational #Webinar #LivePresentation

3

On May 20, 2024, the (CFSRE) distributed analertregarding proliferation of medetomidine in multiple parts of the country.In response to the alert, we wanted to share our findings from when Aegis began testing for medetomidine in Q2-2023 to help raise awareness of theof the potential consequences of this drug in communities and the potential additive risk of this substance when found with other drugs like illicitly-manufactured fentanyl, xylazine, or other central nervous system depressants.As substances within circulation continue to change rapidly, our goal is to remain diligent in updating testing methodologies to reflect drugs that are in use and provide clinicians an opportunity to identify at-risk individuals. For more information on our NPS testing, please contact us. https://lnkd.in/e6ADZYnw

14

Gabapentin can be efficacious when co-prescribed in the management of pain or pain-related conditions, AUD, and some forms of anxiety disorders. Still, gabapentin can be dangerous when used with CNS depressants or in high doses alone. Those who have a history of opioid abuse may be at the highest risk of gabapentin misuse and abuse.On May 28th, Aegis is presenting a webinar discussing the highlights and challenges of gabapentin. Register here: https://lnkd.in/epgD3KnE#AegisLabs #Alcohol #Amphetamines #Antidepressants #Benzodiazepines #Buprenorphine #Gabapentin #Opioids #Clinical #Educational #Webinar #LivePresentation

6

Please join us for an educational webinar on the highlights and challenges of Gabapentin, hosted by Dr. Kristin Hillman, Clinical Pharmacist, Aegis Sciences Corporation.Register Here: https://lnkd.in/epgD3KnE#AegisLabs #Alcohol #Amphetamines #Antidepressants #Benzodiazepines #Buprenorphine #Gabapentin #Opioids #Clinical #Educational #Webinar #LivePresentation

8